Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.

Stock Information for Sonoma Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.